Showing 6101-6110 of 8826 results for "".
- Panel Agrees on Key Recommendations for Oral Minoxidil Usehttps://practicaldermatology.com/news/panel-agrees-key-recommendations-oral-minoxidil-use/2468659/A new international consensus statement offers guidance on the off-label use of low-dose oral minoxidil (LDOM) for managing hair loss. The
- Acne Insights: Strategies and Solutions at 2024 SDPA Fallhttps://practicaldermatology.com/news/acne-insights-strategies-and-solutions-2024-sdpa-fall/2468634/The SDPA’s 22nd Annual Fall Dermatology Conference was held last week at the Fontainebleau in Las Vegas. Conference Medical Director Hilary Baldwin, MD, joined Shanna Miranti, MPAS, PA-C, in a discussion called “Acne Insights: Expert Strategies and Solutions from the Pros.” The presentatio
- Analyses: Ruxolitinib Cream Reduces AD Symptom Burden in 12 Hourshttps://practicaldermatology.com/news/analyses-ruxolitinib-cream-reduces-ad-symptom-burden-12-hours/2468615/Ruxolitinib cream significantly reduced skin pain and improved patient-reported outcomes (PROs) in individuals with mild-to-moderate atopic dermatitis (AD), with improvements sustained over 52 weeks, according to data from the TRuE-AD1 and TRuE-AD2 studies. Researchers the results publishi
- Botanix Announces Expanded Payer Coverage for Sofdrahttps://practicaldermatology.com/news/botanix-announces-expanded-payer-coverage-sofdra/2468602/Botanix announced today that Ascent Health, second largest Payer (insurer) organization in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%, for the treatment of primary axillary hyperhydrosis. According to a press release from Botanix, Ascent represents approximat
- New AD Research Indicates 'New Standards of Care'https://practicaldermatology.com/news/new-ad-research-indicates-new-standards-care/2468544/The bar has been raised for atopic dermatitis (AD). That was the message in “Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis,” a presentation from Drs. Christopher Bunick, Brad Glick, and Alexandra Gol
- FDA Approves Emrosi for Rosaceahttps://practicaldermatology.com/news/fda-approves-emrosi-rosacea-treatment/2468543/The US Food and Drug Administration (FDA) has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) as a treatment for inflammatory lesions of rosacea in adults. According to a press release from the manufacturer, Journey Medical (in partnership with Dr.
- Positive Results for Guselkumab for Moderate PsO Patientshttps://practicaldermatology.com/news/positive-results-guselkumab-moderate-pso-patients/2468490/Guselkumab treatment resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, according to data presented at the 44th Annual Fall Clinical Dermatology Conferenc
- Details Revealed for Upcoming Phase 2 Study for New AD Drug from Apogeehttps://practicaldermatology.com/news/details-revealed-upcoming-phase-2-study-new-ad-drug-apogee/2468489/Apogee Therapeutics’ half-life-extended monoclonal antibody APG777 for atopic dermatitis was the subject of a poster presented by Dr. Emma Guttman-Yassky and others at the 44th Annual Fall Clinical Dermatology Conference. The poster detailed the design of the phase 2 APEX study. “IL
- Promising Pipeline for CSU Optionshttps://practicaldermatology.com/news/promising-pipeline-csu-options/2468488/Cleveland Clinic allergist Dr. David Lang joined Dr. Dawn Merritt and Dr. Brad P. Glick to discuss chronic spontaneous urticaria (CSU) at the 44th Annual Fall Clinical Dermatology Conference and noted that the future is very promising. “Our recent understanding of chronic urticaria has imp
- LEVEL UP: Switching from Dupilumab to Upadacitinib Promising for AD Patientshttps://practicaldermatology.com/news/level-up-switching-from-dupilumab-to-upadacitinib-promising-for-ad-patients/2468483/New research presented at the 44th Annual Fall Clinical Dermatology Conference offered compelling results from th